Valuation: Insulet Corporation

Market Cap 11.55B 10.03B 9.35B 8.59B 16.25B 1,099B 16.43B 110B 43.11B 549B 43.39B 42.44B 1,821B P/E 2026 *
27.1x
P/E 2027 * 20.9x
Enterprise Value 11.62B 10.09B 9.41B 8.65B 16.35B 1,106B 16.53B 111B 43.37B 553B 43.65B 42.7B 1,831B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 2.86x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day-1.70%
1 week-0.39%
Current month+0.89%
1 month+1.42%
3 months-2.67%
6 months-33.60%
Current year-41.31%
1 week 161.62
Extreme 161.6186
172.1
1 month 152.78
Extreme 152.78
172.92
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

1,355 0.0019%
7/1/26 A Other

Director

0 0%
6/30/26 A Free

Director

151 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-0.39%-42.03%-36.60% 11.75B
-1.55%-1.69%-18.83%-2.03% 185B
-0.55%-0.78%-3.84%+2.57% 111B
-0.68%-4.16%+4.30%+65.26% 60B
+0.06%+9.13%+41.76%+55.21% 53.9B
-0.05%+2.27%-4.91%-37.18% 46.9B
+3.88%+3.78% - - 34.22B
-0.42%+16.15%+14.02%-27.75% 32.95B
+0.24%+3.49%+46.30%-7.01% 24.49B
+0.09%+1.09%+1.93%+3.03% 22.67B
Average -0.06%+2.74%+4.30%+1.72% 58.32B
Weighted average by Cap. -0.47%+0.80%-0.90%+6.57%

Financials

2026 *2027 *
Net sales 3.32B 2.88B 2.69B 2.47B 4.67B 316B 4.72B 31.69B 12.39B 158B 12.47B 12.19B 523B 3.93B 3.41B 3.18B 2.92B 5.52B 374B 5.58B 37.48B 14.65B 187B 14.75B 14.42B 619B
Net income 431M 374M 349M 320M 606M 40.98B 613M 4.11B 1.61B 20.49B 1.62B 1.58B 67.88B 565M 490M 457M 420M 794M 53.7B 803M 5.39B 2.11B 26.84B 2.12B 2.07B 88.95B
Net Debt 69.76M 60.57M 56.48M 51.88M 98.12M 6.64B 99.2M 666M 260M 3.32B 262M 256M 10.99B -340M -295M -275M -253M -478M -32.34B -483M -3.25B -1.27B -16.17B -1.28B -1.25B -53.57B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
04/08/26 $166.82 -1.70% 1,749,019
03/08/26 $169.70 +2.63% 1,408,011
31/07/26 $165.35 -0.20% 1,314,052
30/07/26 $165.68 -2.90% 1,215,698
29/07/26 $170.62 +1.88% 1,126,164
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
166.82USD
Average target price
235.54USD
Spread / Average Target
+41.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock